Sysmex Continuing to Participate in the Global Health Innovative Technology Fund
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to continue participating in the Global Health Innovative Technology Fund (GHIT Fund).
Rapid globalization in recent years has led to an increase in diseases crossing national borders, which has become a global problem. In particular, halting the spread of the world’s three leading infectious diseases—HIV/AIDS, tuberculosis and malaria—as well as other diseases, was selected as one of the United Nation’s Sustainable Development Goals (SDGs) in 2015. This is an issue that needs to be addressed internationally.
Sysmex is developing testing technologies targeting malaria, dengue fever, HIV and other diseases, as well as developing products to contribute to the diagnosis of infectious diseases in emerging markets and developing countries.
The GHIT Fund states its vision as “one in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized world.” We are participating in this fund for the three-year period that began in 2015.
The GHIT Fund was established as the first Japanese public-private partnership with members including representatives from the Japanese government, the United Nations Development Programme (UNDP), the pharmaceutical industry, and the Bill & Melinda Gates Foundation. By promoting collaboration among Japanese and overseas research institutions and providing grant funding, the GHIT Fund encourages drug discovery and the development of diagnostic reagents.
In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we have decided to extend our provision of donations for a five-year period from 2018.
By participating in the GHIT Fund, we will move forward with initiatives to develop and provide new reagents for infectious diseases in the aim of eradicating infectious diseases in developing countries.
Sysmex continues providing trust and confidence to customers globally, including developing countries, by contributing to standardization and an improved quality of healthcare.
About the GHIT Fund
The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization that promotes the development of Japanese drugs, vaccines and diagnostics with the cooperation of pharmaceutical companies, academia and research institutions in the aim of controlling infectious diseases that are particularly widespread in developing countries, including HIV/AIDS, tuberculosis, malaria and neglected tropical diseases (NTDs).
See https://www.ghitfund.org/en for more details on the GHIT Fund.
Information contained in the press release is current as of the date of the announcement, but may be subject to change without prior notice.